NASDAQ:PMD

Psychemedics - PMD Stock Forecast, Price & News

$5.72

+0.09 (+1.60%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.71
▼
$5.75
50-Day Range: $5.70
▼
$6.66
52-Week Range: $5.61
▼
$8.00

Volume: 8,044 shs
Average Volume: 10,382 shs
Market Capitalization: $32.29 million

P/E Ratio: N/A
Dividend Yield: 4.91%
Price Target: N/A

Psychemedics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.20% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: -0.32
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.42 out of 5 stars

Medical Sector

997th out of 1,047 stocks

Medical Laboratories Industry

25th out of 26 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Psychemedics.

4.0

Short Interest

Percentage of Shares Shorted
0.20% of the float of Psychemedics has been sold short.
Short Interest Ratio / Days to Cover
Psychemedics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Psychemedics has recently decreased by 3.49%, indicating that investor sentiment is improving.

1.7

Dividend Strength

Dividend Leadership
Psychemedics is a leading dividend payer. It pays a dividend yield of 4.91%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Psychemedics has only been increasing its dividend for 1 years.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PMD.

2.0

News and Social Media Coverage

News Sentiment
Psychemedics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Psychemedics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for PMD on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Psychemedics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Psychemedics insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.70% of the stock of Psychemedics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 38.13% of the stock of Psychemedics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Psychemedics is -15.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Psychemedics is -15.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Psychemedics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Psychemedics (NASDAQ:PMD) Stock

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

PMD Stock News Headlines

November 29, 2022 | americanbankingnews.com

Psychemedics Co. (PMD) To Go Ex-Dividend on December 1st

November 12, 2022 | finance.yahoo.com

Psychemedics Third Quarter 2022 Earnings: US$0.02 loss per share (vs US$0.13 profit in 3Q 2021)

November 9, 2022 | finance.yahoo.com

Psychemedics Corporation Reports Third Quarter 2022 Financial Results and Declares Quarterly Cash Dividend

November 7, 2022 | finance.yahoo.com

One Psychemedics Corporation (NASDAQ:PMD) insider upped their stake by 13% in the previous year

October 4, 2022 | reuters.com

PMD.O - Psychemedics Corp. | Stock Price & Latest News | Reuters

September 8, 2022 | reuters.com

PMD.OQ - Psychemedics Corp. | Stock Price & Latest News | Reuters

August 19, 2022 | nasdaq.com

Don't Buy Psychemedics Corporation (NASDAQ:PMD) For Its Next Dividend Without Doing These Checks - Nasdaq

August 18, 2022 | finance.yahoo.com

Don't Race Out To Buy Psychemedics Corporation (NASDAQ:PMD) Just Because It's Going Ex-Dividend

August 11, 2022 | streetinsider.com

Form 10-Q PSYCHEMEDICS CORP For: Jun 30 - StreetInsider.com

August 9, 2022 | greenwichtime.com

Psychemedics: Q2 Earnings Snapshot - Greenwich Time

August 9, 2022 | finance.yahoo.com

Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend

August 9, 2022 | globenewswire.com

Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend - GlobeNewswire

July 18, 2022 | nz.finance.yahoo.com

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

July 6, 2022 | streetinsider.com

Form DEF 14A PSYCHEMEDICS CORP For: Aug 12 - StreetInsider.com

June 16, 2022 | globenewswire.com

Global Drug Screening Laboratory Services Market (2022 to 2027) - Technological Advancements to Improve the Accuracy of Drug Screening Presents Opportunities - GlobeNewswire

June 16, 2022 | finance.yahoo.com

Insights on the Drug Screening Laboratory Services Global Market to 2027 - Featuring MPD, Omega Laboratories and Orasure Technologies Among Others - Yahoo Finance

June 16, 2022 | finance.yahoo.com

Global Drug Screening Laboratory Services Market (2022 to 2027) - Technological Advancements to Improve the Accuracy of Drug Screening Presents Opportunities - Yahoo Finance

June 15, 2022 | businesswire.com

The Worldwide Drug Screening Laboratory Services Industry is Projected to Reach $13.6 Billion by 2027 - ResearchAndMarkets.com - Business Wire

June 10, 2022 | finance.yahoo.com

Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.’s Retirement after More than 20 Years of Dedicated Service - Yahoo Finance

June 9, 2022 | globenewswire.com

Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.'s Retirement after More than 20 Years of Dedicated Service - GlobeNewswire

June 9, 2022 | finance.yahoo.com

Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.’s Retirement after More than 20 Years of Dedicated Service

June 7, 2022 | finance.yahoo.com

Capital Allocation Trends At Psychemedics (NASDAQ:PMD) Aren't Ideal

May 17, 2022 | globenewswire.com

Global Drug Screening Market to Witness Steady Expansion Growth of USD 25.12 billion by 2027 : Fior Markets - GlobeNewswire

May 11, 2022 | nasdaq.com

Daily Dividend Report: PSX,PMD,MMM,PRU,DHR - Nasdaq

May 10, 2022 | seekingalpha.com

Psychemedics raises dividend by 40% to $0.07 - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

PMD Company Calendar

Last Earnings: 4/23/2019
Ex-Dividend for 9/9 Dividend: 8/23/2022
Dividend Payable: 9/09/2022
Today: 12/01/2022
Ex-Dividend for 12/16 Dividend: 12/01/2022
Dividend Payable: 12/16/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 4/04/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PMD
CUSIP: N/A
CIK: 806517
Web: www.psychemedics.com
Phone: (978) 206-8220
Fax: 978-264-9236
Employees: 139
Year Founded: 1985

Profitability

EPS (Most Recent Fiscal Year): ($0.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-670,000.00
Net Margins: -7.77%
Pretax Margin: -10.53%
Return on Equity: -16.68%
Return on Assets: -9.67%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 1.74
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $24.91 million
Price / Sales: 1.30
Cash Flow: $0.54 per share
Price / Cash Flow: 10.50
Book Value: $2.08 per share
Price / Book: 2.75

Miscellaneous

Outstanding Shares: 5,645,000
Free Float: 4,872,000
Market Cap: $32.29 million
Optionable: Not Optionable
Beta: 0.53

Social Links

Key Executives

Mr. Raymond C. Kubacki (Age 77)
Chairman, CEO & Pres
Comp: $473.2k

Mr. Charles M. Doucot IV (Age 56)
Exec. VP
Comp: $262.75k

Dr. Michael I. Schaffer Ph.D. (Age 77)
VP of Laboratory Operations
Comp: $248.02k

Dr. Werner A. Baumgartner Ph.D.
Founder

Ms. Annette Baumgartner
Founder

Ms. Sarah Ashby
VP & Gen. Counsel

Mr. Patrick J. Kinney Jr.
Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PMD Stock - Frequently Asked Questions

How have PMD shares performed in 2022?: Psychemedics' stock was trading at $7.02 at the start of the year. Since then, PMD stock has decreased by 18.5% and is now trading at $5.72.
View the best growth stocks for 2022 here.
When is Psychemedics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our PMD earnings forecast.
How were Psychemedics' earnings last quarter?: Psychemedics Co. (NASDAQ:PMD) issued its quarterly earnings data on Tuesday, April, 23rd. The company reported $0.11 earnings per share for the quarter. The company earned $9.82 million during the quarter. Psychemedics had a negative net margin of 7.77% and a negative trailing twelve-month return on equity of 16.68%.
How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?: Psychemedics declared a quarterly dividend on Wednesday, November 9th. Shareholders of record on Friday, December 2nd will be given a dividend of $0.07 per share on Friday, December 16th. This represents a $0.28 annualized dividend and a yield of 4.90%. The ex-dividend date is Thursday, December 1st.
Read our dividend analysis for PMD.
Is Psychemedics a good dividend stock?: Psychemedics (NASDAQ:PMD) pays an annual dividend of $0.28 per share and currently has a dividend yield of 4.91%. PMD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for PMD.
What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?: 6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.

What other stocks do shareholders of Psychemedics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).
What is Psychemedics' stock symbol?: Psychemedics trades on the NASDAQ under the ticker symbol "PMD."
Who are Psychemedics' major shareholders?: Psychemedics' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.44%) and Wedbush Securities Inc. (0.35%). Insiders that own company stock include Fred J Weinert, Michael I Schaffer, Peter Kamin and Raymond C Kubacki Jr.
View institutional ownership trends.
How do I buy shares of Psychemedics?: Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Psychemedics' stock price today?: One share of PMD stock can currently be purchased for approximately $5.72.
How much money does Psychemedics make?: Psychemedics (NASDAQ:PMD) has a market capitalization of $32.29 million and generates $24.91 million in revenue each year. The company earns $-670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.
How many employees does Psychemedics have?: The company employs 139 workers across the globe.
How can I contact Psychemedics?: Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The official website for the company is www.psychemedics.com. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236.

This page (NASDAQ:PMD) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial